Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (DOSE): A registry for characterizing anaemia management and outcomes in oncology patients

Clinical Drug Investigation

Volumn 28, Issue 3, 2008, Pages 159-167

  Larholt, Kay ^a   Pashos, Chris L ^a   Wang, Qin ^a   Bookhart, Brahim ^b   McKenzie, R Scott ^b   Piech, Catherine Tak ^b  

^a ABT ASSOCIATES   (United States)

^b Ortho Biotech Products LP   (United States)

Author keywords

Anaemia; Cancer; Darbepoetin alfa, therapeutic use; Epoetin alfa, therapeutic use; Outcomes research; Resource use

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; DECISION MAKING; DEMOGRAPHY; DOSE RESPONSE; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE;

EID: 39049138428     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828030-00003     Document Type: Article

References (36)

1. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998 Jun; 25 (3 Suppl. 7): 43-6
2. Sobrero A, Puglisi F, Guglielmi A, et al. Fatigue: a main component of anemia symptomatology. Semin Oncol 2001 Apr; 28 (2 Suppl. 8): 15-8
3. Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001 Jun 15; 91 (12): 2214-21
4. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999 Oct 6; 91 (19): 1616-34
5. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002 Oct 1; 20 (19): 4083-107
6. National Comprehensive Cancer Network. Cancer and treatment-related anemia: version 3.2007 [online]. Available from URL: http://www.nccn.org/ professionals/physician_gls/PDF/anemia.pdf [Accessed 2007 Aug 2]
7. Aranesp® (darbepoetin alfa) [prescribing information]. Thousand Oaks (CA): Amgen Inc., 2007 Apr
8. Procrit® (epoetin alfa) [prescribing information]. Raritan (NJ): Ortho Biotech Products, 2007 Mar
9. Thatcher N. Management of chemotherapy-induced anemia in solid tumors. Semin Oncol 1998 Jun; 25 (3 Suppl. 7): 23-6
10. Ferrario E, Ferrari L, Bidoli P, et al. Treatment of cancer-related anemia with epoetin alfa: a review. Cancer Treat Rev 2004 Oct; 30 (6): 563-75
11. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005 Mar 10; 352 (10): 1011-23
12. Stasi R, Amadori S, Littlewood TJ, et al. Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns. Oncologist 2005 Aug; 10 (7): 539-54
13. Patton J, Kuzur M, Liggett W, et al. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy. Oncologist 2004; 9 (1): 90-6
14. Vadhan-Raj S, Mirtsching B, Charu V, et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol 2003 Jul-Aug; 1 (2): 131-8
15. Steensma DP, Molina R, Sloan JA, et al. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol 2006 Mar 1; 24 (7): 1079-89
16. Hesketh PJ, Arena F, Patel D, et al. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have monmyeloid malignancies. Cancer 2004 Feb 15; 100 (4): 859-68
17. Henry DH, Gordan LN, Charu V, et al. Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia. Curr Med Res Opin 2006 Jul; 22 (7): 1403-13
18. Montoya VP, Xie J, Williams D, et al. An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy. Support Care Cancer 2007 Dec; 15 (12): 1385-92
19. Waltzman R, Croot C, Justice GR, et al. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 2005 Sep; 10 (8): 642-50
20. Schwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004; 9 (6): 696-707
21. Glaspy J, Vadhan-Raj S, Patel R, et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol 2006 May 20; 24 (15): 2290-7
22. Mark TL, McKenzie RS, Fastenau J, et al. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents. Curr Med Res Opin 2005 Sep; 21 (9): 1347-54
23. Herrington JD, Davidson SL, Tomita DK, et al. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Am J Health Syst Pharm 2005 Jan 1; 62 (1): 54-62
24. Schwartzberg L, Shiffman R, Tomita D, et al. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clin Ther 2003 Nov; 25 (11): 2781-96
25. Franciosa JA. The potential role of community-based registries to complement the limited applicability of clinical trial results to the community setting: heart failure as an example. Am J Manage Care 2004 Jul; 10 (7 Pt 2): 487-92
26. Weaver AL, Lautzenheiser RL, Schiff MH, et al. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Curr Med Res Opin 2006 Jan; 22 (1): 185-98
27. Gibofsky A, Palmer WR, Goldman JA, et al. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study. Curr Med Res Opin 2006 Jan; 22 (1): 169-83
28. Department of Health and Human Services. Health Insurance Portability and Accountability Act (HIPAA) of 1996 [online]. Available from URL: http://www.hhs.gov/ocr/hipaa/FinalEnforcementRule06.pdf [Accessed 2008 Jan 30].
29. Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997 Feb; 13 (2): 63-74
30. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997 Jul; 34 (3 Suppl. 2): 13-9
31. Cella D. FACT-An (version 4) [online]. Available from URL: http://www.facit.org/qview/qlist.aspx [Accessed 2007 Sep 25]
32. SAS Institute Inc. SAS/Stat 9.1 user's guide. Cary (NC): SAS Institute Inc., 2004
33. Gliklich RE, Dreyer NA, editors. Registries for evaluating patient outcomes: a user's guide (prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. dba Outcome] under Contract No. HHSA29020050035I TO1). AHRQ Publication No. 07-EHC001-1. Rockville (MD): Agency for Healthcare Research and Quality, 2007 Apr [online]. Available from URL: http://effectivehealthcare.ahrq.gov/reports/ topic.cfm?.topic = 0&sid = 2&rType = 11 [Accessed 2007 Sep 25]
34. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003 Sep 24; 290 (12): 1624-32
35. Neuss MN, Desch CE, McNiff KK, et al. A process for measuring the quality of cancer care: the Quality Oncology Practice Initiative. J Clin Oncol 2005 Sep 1; 23 (25): 6233-9
36. Lefebvre P, Gosselin A, McKenzie RS, et al. Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations. Curr Med Res Opin 2006 Sep; 22 (9): 1623-31